Tomorrow BioSpecifics Tech. (Nasdaq-BTSC) will hold its annual meeting. I am a shareholder but will not be able to attend. However, I still believe that this stock has the potential for a real run from current price levels. BTSC is the original developer of injectable collangenase. BTSC has a great relationship with Auxilium (Nasdaq-AUXL) which provides for substantial royalty payements. In recent days a research report was issued placing a 12-month price target of $40 on the BTSC shares. In my view, BioSpecifics is very undervalued and the just mentioned price target seems reasonable.